Conference News

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Featured

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

“This is the largest KCCQ benefit ever reported in any trial with a drug for HFrEF or HFpEF,” Milton Packer notes.

September 13, 2021

Latest Conference News

See All

Left Main Guideline Review Looms as EACTS Surgeons Urge CABG First

By Michael O'Riordan

October 19, 2021
More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

By Michael O'Riordan

October 18, 2021
EXAMINATION Confirms Poor 10-Year Prognosis in Diabetic Patients Post-STEMI

By Michael O'Riordan

October 15, 2021
Crushed Prasugrel Loading Dose Still No Benefit at 1 Year in COMPARE CRUSH

By Yael L. Maxwell

October 15, 2021
No Harm From Thrombolytics in SCAD Patients With STEMI

By Michael O'Riordan

October 13, 2021
LAA Closure Feasible in Patients With Thrombus: Registry

By Michael O'Riordan

October 13, 2021

Country